HALOZYME THERAPEUTICS, INC. 4

Halozyme Therapeutics CEO Helen Torley exercised 1,923 options at $12.07 and sold 1,923 Halo common shares around $79–80 on July 8, 2026 under a Rule 10b5-1 plan.

On July 8, 2026, Halozyme Therapeutics, Inc. President and CEO Helen Torley exercised 1,923 stock options at an exercise price of $12.07 per share and received 1,923 shares of common stock, then sold a total of 1,923 common shares in two open-market transactions at weighted-average prices of $79.276 and $80.187 per share under a pre-arranged Rule 10b5-1 trading plan. The gross option exercise cost was approximately $23,200 and the related sales generated proceeds of roughly $153,000, indicating this was effectively a cashless exercise with limited net change in her overall economic exposure. Following these transactions, Torley continued to beneficially own 767,780 shares of Halozyme common stock, representing an equity stake worth about $61.5 million based on the transaction price context around $80 per share.

Filing Facts

CIK

1159036

Ticker

HALO

Form

4

Source Type

fda

Accession

0001159036-26-000100

Alert Tier

5